Timing of response in patients with relapsed/refractory FLT3 mut+ acute myeloid leukemia treated with gilteritinib. (PubMed, Blood Neoplasia) - Aug 31, 2026 - P3 | "Patients with R/R FLT3-mutated AML should continue gilteritinib monotherapy, if tolerated, for a minimum of 6 cycles because later responses can occur. These trials were registered at www.clinicaltrials.gov as NCT02421939 (ADMIRAL) and NCT03182244 (COMMODORE)."
Journal • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation • FLT3 • NPM1
|
|
Alexander E Perl; Andrew H Wei; Dina Elsouda; Hee-Je Kim; Hisayuki Yokoyama; Jamie Jung-Hee An; Jian Li; Jianxiang Wang; Juan Ariza; June-Won Cheong; Mark J Levis; Nahla Hasabou; Naoko Hosono; Sergey Bondarenko
|